Literature DB >> 22992764

hTERT-based therapy: a universal anticancer approach (Review).

Mu-Han Lü1, Zhong-Li Liao, Xiao-Yan Zhao, Ya-Han Fan, Xian-Long Lin, Dian-Chun Fang, Hong Guo, Shi-Ming Yang.   

Abstract

Human telomerase reverse transcriptase (hTERT) has been identified as a major protein involved in aberrant cell proliferation, immortalization, metastasis and stemness maintenance in a majority of tumors, yet it has little or no expression in normal somatic cells. During the past few years, the development of hTERT-based therapies such as immunotherapy, suicide gene therapy and small-molecule interfering therapy have become critical and specific for eradicating all types of cancer. Here, current knowledge regarding hTERT and its involvement in various cancers and its role as a target of cancer therapies are reviewed. Additionally, hurdles to new cancer therapy development and new therapeutic opportunities are described, along with areas that require further investigation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22992764     DOI: 10.3892/or.2012.2036

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  12 in total

1.  Targeting EBV-LMP1 DNAzyme enhances radiosensitivity of nasopharyngeal carcinoma cells by inhibiting telomerase activity.

Authors:  Lifang Yang; Zhijie Xu; Liyu Liu; Xiangjian Luo; Jingchen Lu; Lunquan Sun; Ya Cao
Journal:  Cancer Biol Ther       Date:  2013-10-21       Impact factor: 4.742

2.  CPSF4 activates telomerase reverse transcriptase and predicts poor prognosis in human lung adenocarcinomas.

Authors:  Wangbing Chen; Lijun Qin; Shusen Wang; Mei Li; Dingbo Shi; Yun Tian; Jingshu Wang; Lingyi Fu; Zhenglin Li; Wei Guo; Wendan Yu; Yuhui Yuan; Tiebang Kang; Wenlin Huang; Wuguo Deng
Journal:  Mol Oncol       Date:  2014-02-14       Impact factor: 6.603

Review 3.  Human telomerase reverse transcriptase regulation by DNA methylation, transcription factor binding and alternative splicing (Review).

Authors:  Brittany A Avin; Christopher B Umbricht; Martha A Zeiger
Journal:  Int J Oncol       Date:  2016-10-20       Impact factor: 5.650

4.  Induction of antitumor cytotoxic lymphocytes using engineered human primary blood dendritic cells.

Authors:  Long Wu; Huan Zhang; Yixing Jiang; Robert C Gallo; Hua Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-19       Impact factor: 11.205

5.  Down regulation of human telomerase reverse transcriptase (hTERT) expression by BIBR1532 in human glioblastoma LN18 cells.

Authors:  C Lavanya; Manjunatha M Venkataswamy; M K Sibin; M M Srinivas Bharath; G K Chetan
Journal:  Cytotechnology       Date:  2018-03-15       Impact factor: 2.058

6.  Triptolide inhibits human telomerase reverse transcriptase by downregulating translation factors SP1 and c-Myc in Epstein-Barr virus-positive B lymphocytes.

Authors:  Cong Long; Qiu-Bo Xu; Li Ding; Liu Yang; Wei Ji; Feng Gao; Yong Ji
Journal:  Oncol Lett       Date:  2021-02-10       Impact factor: 2.967

Review 7.  Molecular mechanisms of long noncoding RNAs on gastric cancer.

Authors:  Tianwen Li; Xiaoyan Mo; Liyun Fu; Bingxiu Xiao; Junming Guo
Journal:  Oncotarget       Date:  2016-02-23

8.  Arginine deiminase expressed in vivo, driven by human telomerase reverse transcriptase promoter, displays high hepatoma targeting and oncolytic efficiency.

Authors:  Hui Jiang; Song Guo; Dan Xiao; Xuzhao Bian; Jie Wang; Ying Wang; Huiting Zhou; Jun Cai; Zhongliang Zheng
Journal:  Oncotarget       Date:  2017-06-06

9.  Knockdown of hTERT and Treatment with BIBR1532 Inhibit Cell Proliferation and Invasion in Endometrial Cancer Cells.

Authors:  Weimin Kong; Nenan Lv; Weiya Z Wysham; Dario R Roque; Tongqing Zhang; Simeng Jiao; Dan Song; Jiao Chen; Victoria L Bae-Jump; Chunxiao Zhou
Journal:  J Cancer       Date:  2015-11-01       Impact factor: 4.207

10.  Telomerase reverse transcriptase mediates EMT through NF-κB signaling in tongue squamous cell carcinoma.

Authors:  Yan Wu; Chunxiang Bian; Chunlin Zhen; Liu Liu; Zhenghong Lin; Muhammad Farrukh Nisar; Mei Wang; Jörg W Bartsch; Enyi Huang; Ping Ji; Li Yang; Yanhong Yu; Junfeng Yang; Xuemei Jiang; Julia Li Zhong
Journal:  Oncotarget       Date:  2017-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.